Abstract

A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine. He achieved a complete remission (CR) after two cycles of therapy, and he remained in remission during 1 year of treatment. He developed recurrent AML after discontinuation of decitabine. He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine.

Original languageEnglish
Pages (from-to)543-545
Number of pages3
JournalAmerican journal of hematology
Volume81
Issue number7
DOIs
StatePublished - Jul 1 2006

Keywords

  • Acute myeloid leukemia
  • Decitabine
  • Myelodysplastic syndromes

Fingerprint

Dive into the research topics of 'Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine'. Together they form a unique fingerprint.

Cite this